#United States #Pensacola #Pulmonary Nodule #Circulogene #LungLifeAI

Circulogene Launches LungLifeAI® for Indeterminate Pulmonary Nodule Assessment

In a groundbreaking stride for lung health diagnostics, Circulogene has unveiled LungLifeAI®, an innovative blood-based test specifically designed to assess indeterminate pulmonary nodules (IPNs) detected via CT imaging. This exclusive commercial launch marks a significant advancement in clinical decision-making for healthcare providers handling potentially malignant lung nodules.

When faced with a lung nodule identified through a CT scan, clinicians often grapple with the challenge of whether to proceed with a biopsy, particularly for nodules that are smaller than 2 cm. Traditional imaging can leave many questions unanswered, creating a critical need for an enhanced diagnostic tool. This is where LungLifeAI® comes into play.

LungLifeAI® utilizes cutting-edge artificial intelligence to provide high-performance molecular biomarker analysis. Certifiably clinically validated, the test boasts impressive performance metrics: an 80% Positive Predictive Value (PPV), along with 77% sensitivity and 74% specificity, offering a reliable means of assessing malignancy risk earlier and more accurately than traditional methods could allow.

Simplifying the Testing Process

One of the standout features of LungLifeAI® is its user-friendly approach. Utilizing a simple blood collection kit, the test streamlines the diagnostic process for both patients and healthcare providers. Additionally, Circulogene offers mobile phlebotomy options, ensuring that collection can take place in the most convenient settings for patients, thus reducing the anxiety often associated with medical testing.

The test operates by analyzing chromosomal signal patterns from thousands of cells within the blood sample, providing deep molecular insights into the behavior and risk associated with lung nodules. This sophisticated approach allows clinicians not only to make informed decisions about the necessity of biopsies but also paves the way for more tailored treatment plans that can be initiated at an earlier stage.

A Statement from the CEO

Mike Mullen, CEO of Circulogene, emphasized the importance of clarity for physicians when assessing patients with IPNs, stating, “Our physicians need greater clarity when assessing patients with indeterminate pulmonary nodules. LungLifeAI® complements our OncoGenLDx tumor profiling test by providing actionable insights when CT imaging isn’t enough. With a simple blood draw, we help physicians determine which small nodules require biopsy for a timely treatment plan.”

This digital healthcare innovation is not just a testament to the capabilities of modern technology but also symbolizes a step forward in the commitment to patient care and better health outcomes.

About Circulogene

Circulogene, based in Birmingham, Alabama, is a leader in precision diagnostics, employing advanced liquid biopsy technologies to deliver rapid and actionable results. With a lab that holds CAP and CLIA certifications, Circulogene specializes in molecular testing solutions that enhance cancer treatment personalization and disease progression tracking. The company remains dedicated to supporting oncologists and healthcare systems with fast turnaround and broad genomic coverage, ultimately aiming to improve patient outcomes through scientific advancement and dedicated service.

For additional information about LungLifeAI® and Circulogene’s offerings, visit Circulogene or explore LungLifeAI.